METHODS: Seventy-one medication-naïve patients and 71 healthy controls (HCs) aged 18 to 28 underwent clinical interviews, Conners' Adult ADHD Rating Scale (CAARS) questionnaire, functional near-infrared spectroscopy (fNIRS), oculomotricity task, and Conners' Continuous Performance Task (CPT) 3rd edition. Student's t-tests with Bonferroni's correction were performed to compare the performance between groups, and logistic regression was used for classification.
RESULTS: ADHD patients had significantly lower frontal hemodynamic response during verbal fluency task (VFT) (P = 0.0003), more anticipatory eye movements during overlap task (P = 0.0006), higher latency (P
METHODS: Single-factor and orthogonal experiments were conducted to investigate the impacts of sweet osmanthus-to-white tea ratio and the concentrations of β-cyclodextrin, erythritol, and citric acid on sensory properties and total flavonoids content (TFC) of IOWT. Mixtures of the dried ingredients were spray-dried to produce IOWT.
RESULTS AND DISCUSSION: The optimal formulation of IOWT was as follows: sweet osmanthus-towhite tea ratio of 1:5, 4% β-cyclodextrin, 6% erythritol, and 0.5% citric acid. This optimized IOWT formulation obtained the highest sensory score of 89.5 and a TFC of 25.76%. Using ascorbic acid as a positive control, the in vitro antioxidant activities of the optimized IOWT formulation were assessed by measuring its ability to scavenge DPPH radicals, hydroxyl radicals, superoxide anion radicals, and ABTS radicals. At a concentration of 1.0 mg/mL, the optimized IOWT formulation exhibited scavenging rates of 88.01, 94.99, 97.57, and 99.11% against DPPH, hydroxyl radicals, superoxide anion radicals, and ABTS radicals, respectively, indicating strong in vitro antioxidant activities of IOWT. This study demonstrated promising potential for the development of novel white tea-based products.
METHODS: We carried out a systematic search of all available RCTs up to June 2019 in the following electronic databases: PubMed, Scopus, Web of Science and Google Scholar. Pooled weight mean difference (WMD) of the included studies was estimated using random-effects model.
RESULTS: A total of 27 articles were included in this meta-analysis, with walnuts dosage ranging from 15 to 108 g/d for 2 wk to 2 y. Overall, interventions with walnut intake did not alter waist circumference (WC) (WMD: -0.193 cm, 95 % CI: -1.03, 0.64, p = 0.651), body weight (BW) (0.083 kg, 95 % CI: -0.032, 0.198, p = 0.159), body mass index (BMI) (WMD: -0.40 kg/m,295 % CI: -0.244, 0.164, p = 0.703), and fat mass (FM) (WMD: 0.28 %, 95 % CI: -0.49, 1.06, p = 0.476). Following dose-response evaluation, reduced BW (Coef.= -1.62, p = 0.001), BMI (Coef.= -1.24, p = 0.041) and WC (Coef.= -5.39, p = 0.038) were significantly observed through walnut intake up to 35 g/day. However, the number of studies can be limited as to the individual analysis of the measures through the dose-response fashion.
CONCLUSIONS: Overall, results from this meta-analysis suggest that interventions with walnut intake does not alter BW, BMI, FM, and WC. To date, there is no discernible evidence to support walnut intake for improving anthropometric indicators of weight loss.
METHODS: To determine the antibacterial effectiveness of the MAC against Pseudomonas aeruginosa, we conducted minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) assays. Transmission electron microscopy (TEM) and scanning electron microscopy (SEM) techniques were employed to observe bacterial morphology and biofilm formation. We further performed a biofilm inhibition assay to assess the effect of the MAC on biofilm formation. Whole-transcriptome sequencing and bioinformatics analysis were employed to elucidate the antibacterial mechanism of the MAC. Additionally, the expression levels of differentially expressed genes were validated using the real-time PCR approach.
RESULTS: Our findings demonstrated the antibacterial activity of the MAC against P. aeruginosa. SEM analysis revealed that the MAC can induce morphological changes in bacterial cells. The biofilm assay showed that the MAC could reduce biofilm formation. Whole-transcriptome analysis revealed 1093 differentially expressed genes consisting of 659 upregulated genes and 434 downregulated genes, in response to the MAC treatment. Mechanistically, the MAC inhibited P. aeruginosa growth by targeting metabolic processes, secretion system, signal transduction, and cell membrane functions, thereby potentially compromising the survival of this human pathogen. This study provides valuable insights into the antibacterial and antibiofilm activities of the MAC, a synergistic and cost-effective malic acid combination, which holds promise as a potential therapeutic drug cocktail for treating human infectious diseases in the future.